Cerevel Therapeutics Holdings, Inc. which can be found using ticker (CERE) now have 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 46 and 22 and has a mean target at $36.33. Given that the stocks previous close was at $34.00 this would indicate that there is a potential upside of 6.9%. The day 50 moving average is $27.58 and the 200 moving average now moves to $29.25. The company has a market capitalization of 5.22B. The stock price is currently at: 33.27 USD
The potential market cap would be $5,575,408,531 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of – and a -31.87% return on assets.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Its pipeline with various clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson’s, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy.
